Literature DB >> 15084805

Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.

Sibylle Wenzler1, Elke Schmidt-Eisenlohr, Franz Daschner.   

Abstract

BACKGROUND: In our study the in vitro susceptibility of common pathogens that cause respiratory tract and abdominal wound infections was tested against two newer fluorquinolones (moxifloxacin and gatifloxacin) as well as levofloxacin and azithromycin.
METHODS: 50 isolates each of methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa and Haemophilus influenzae isolated from the respiratory tract and from wounds were tested for their susceptibility to moxifloxacin, gatifloxacin, levofloxacin and azithromycin.
RESULTS: Moxifloxacin proved to be the most active substance against the tested gram-positive pathogens. Gatifloxacin was the most active against P. aeruginosa. Moxifloxacin and gatifloxacin proved to be comparably active against the clinical isolates of E. coli and H. influenzae.
CONCLUSIONS: Moxifloxacin and gatifloxacin display excellent activity against respiratory pathogens as well as nosocomial pathogens causing abdominal wound infections. When treating infections caused by P. aeruginosa the earlier fluorquinolones such as ciprofloxacin or ofloxacin are the substances of choice. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084805     DOI: 10.1159/000077284

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.

Authors:  Andreas D Rink; Heino Stass; Heinz Delesen; Dagmar Kubitza; Karl-Heinz Vestweber
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

2.  Fluoroquinolone therapy for uncomplicated skin and skin structure infections : a retrospective database comparison of treatment duration, failures and charges.

Authors:  Karen N Keating; Howard Friedman; Eleanor M Perfetto
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

3.  Susceptibility of prosthetic biomaterials to infection.

Authors:  J E Losanoff; J M Millis
Journal:  Surg Endosc       Date:  2005-10-24       Impact factor: 3.453

4.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.